You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 28, 2024

Investigational Drug Information for KHK7791


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug KHK7791?

KHK7791 is an investigational drug.

There have been 7 clinical trials for KHK7791. The most recent clinical trial was a Phase 3 trial, which was initiated on March 15th 2021.

The most common disease conditions in clinical trials are Hyperphosphatemia and [disabled in preview]. The leading clinical trial sponsors are Kyowa Kirin Co., Ltd., Kyowa Hakko Kirin Co., Ltd, and [disabled in preview].

There are thirteen US patents protecting this investigational drug and one hundred and twenty-seven international patents.

Recent Clinical Trials for KHK7791
TitleSponsorPhase
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisKyowa Kirin Co., Ltd.Phase 3
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisKyowa Kirin Co., Ltd.Phase 3
Clinical Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisKyowa Kirin Co., Ltd.Phase 3

See all KHK7791 clinical trials

Clinical Trial Summary for KHK7791

Top disease conditions for KHK7791
Top clinical trial sponsors for KHK7791

See all KHK7791 clinical trials

US Patents for KHK7791

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
KHK7791 ⤷  Sign Up sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
KHK7791 ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
KHK7791 ⤷  Sign Up NHE3-binding compounds and methods for inhibiting phosphate transport ARDELYX, INC. ⤷  Sign Up
KHK7791 ⤷  Sign Up Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. (Fremont, CA) ⤷  Sign Up
KHK7791 ⤷  Sign Up Compositions and methods for treating or preventing gut permeability-related disorders Gelesis LLC (Boston, MA) ⤷  Sign Up
KHK7791 ⤷  Sign Up sGC stimulators Cyclerion Therapeutics, Inc. (Cambridge, MA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for KHK7791

Drugname Country Document Number Estimated Expiration Related US Patent
KHK7791 Australia AU2015317818 2034-09-17 ⤷  Sign Up
KHK7791 Brazil BR112017005248 2034-09-17 ⤷  Sign Up
KHK7791 Canada CA2961531 2034-09-17 ⤷  Sign Up
KHK7791 China CN107223125 2034-09-17 ⤷  Sign Up
KHK7791 Eurasian Patent Organization EA201790627 2034-09-17 ⤷  Sign Up
KHK7791 European Patent Office EP3194395 2034-09-17 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.